In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...
HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...
SynuSight Biotech (SynuSight), a clinical-stage biotech company focused on innovative pipeline development for neurodegenerative diseases, today announced the publication of a collaborative study in ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Stockhead on MSN
Alterity in spotlight at medical conferences as MSA clinical research moves toward phase III planning
Presentations at key medical conferences in May support advancement of Alterity’s lead drug ATH434 into Phase III development ...
Good afternoon, and welcome to the Alterity Therapeutics Virtual KOL Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Alterity ...
Patients with multiple-system atrophy often have debilitating orthostatic hypotension. An implanted spinal cord stimulator could help to manage this hypotension and related syncope. New research ...
The buildup of a protein called α-synuclein (ASN) into toxic clumps is a hallmark of synucleinopathies, a group of neurodegenerative diseases that includes Parkinson’s and multiple system atrophy (MSA ...
Multiple system atrophy Parkinsonian type (MSA-P) is a rare neurodegenerative disease that progresses over time. It can cause problems with movement and coordination, digestion, bladder control, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results